| Identification | Back Directory | [Name]
EthanediaMide, N1-(5-chloro-2-pyridinyl)-N2-[(1R,2S,4S)-4-[(diMethylaMino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-Methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]aMino]cyclohexyl]- | [CAS]
1255529-25-9 | [Synonyms]
Edoxaban-15
Enantiomer(RSS)
Edoxaban Impurity 26
Edoxaban (RSS)-Isomer
Edoxaban Isomer (RSS)
Edoxaban iMpurities 10
Edoxaban iMpurities 15
Edoxaban Impurity 10 (1R,2S,4S)
Edoxaban impurity 6/Edoxaban RSS Isomer
N1-(5-chloropyridin-2-yl)-N2-((1R,2S,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazo
(5-chloropyridin-2-yl)-N2-((1R,2S,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl)oxalamide
N1-(5-chloropyridin-2-yl)-N2-((1R,2S,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl)oxalamide
N1-(5-Chloropyridin-2-yl)-N2-((1R,2S,4S)-4-[(dimethylamino)carbonyl]-2-{[5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide
EthanediaMide, N1-(5-chloro-2-pyridinyl)-N2-[(1R,2S,4S)-4-[(diMethylaMino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-Methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]aMino]cyclohexyl]-
Edoxaban impurity 6/Edoxaban RSS Isomer/N1-(5-chloropyridin-2-yl)-N2-((1R,2S,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl)oxalamide | [Molecular Formula]
C24H30ClN7O4S | [MDL Number]
MFCD27987165 | [MOL File]
1255529-25-9.mol | [Molecular Weight]
548.06 |
| Hazard Information | Back Directory | [Uses]
N1-(5-chloropyridin-2-yl)-N2-((1R,2S,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl)oxalamide is a diastereomer of Edoxaban (E555520), an anticoagulant drug which acts as a direct factor Xa inhibitor. N1-(5-chloropyridin-2-yl)-N2-((1R,2S,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl)oxalamide can be used as a pharmceutical standard for detecting impurities in drugs. |
|
|